vs
STANDARD BIOTOOLS INC.（LAB）与UNITED STATES ANTIMONY CORP（UAMY）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是UNITED STATES ANTIMONY CORP的1.5倍（$19.6M vs $13.0M），UNITED STATES ANTIMONY CORP净利率更高（-2.2% vs -177.4%，领先175.2%），UNITED STATES ANTIMONY CORP同比增速更快（131.4% vs -11.5%），UNITED STATES ANTIMONY CORP自由现金流更多（$-15.2M vs $-23.1M），过去两年UNITED STATES ANTIMONY CORP的营收复合增速更高（106.0% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
美国锑业公司是一家从事锑、银、金等矿产资源勘探、开采、加工及销售的自然资源企业，在美国和墨西哥设有生产基地，产品服务于阻燃材料、电池合金、特种化工等领域的全球工业客户。
LAB vs UAMY — 直观对比
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $13.0M |
| 净利润 | $-34.7M | $-286.9K |
| 毛利率 | 48.5% | 20.3% |
| 营业利润率 | -168.5% | -30.1% |
| 净利率 | -177.4% | -2.2% |
| 营收同比 | -11.5% | 131.4% |
| 净利润同比 | -28.8% | 67.5% |
| 每股收益（稀释后） | $-0.09 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | — | $13.0M | ||
| Q3 25 | $19.6M | $8.7M | ||
| Q2 25 | $21.8M | $10.5M | ||
| Q1 25 | $40.8M | $7.0M | ||
| Q4 24 | — | $5.6M | ||
| Q3 24 | $22.1M | $2.6M | ||
| Q2 24 | $22.5M | $3.7M | ||
| Q1 24 | $45.5M | $3.1M |
| Q4 25 | — | $-286.9K | ||
| Q3 25 | $-34.7M | $-4.8M | ||
| Q2 25 | $-33.5M | $181.6K | ||
| Q1 25 | $-26.0M | $546.5K | ||
| Q4 24 | — | $-882.9K | ||
| Q3 24 | $-26.9M | $-727.5K | ||
| Q2 24 | $-45.7M | $202.8K | ||
| Q1 24 | $-32.2M | $-322.8K |
| Q4 25 | — | 20.3% | ||
| Q3 25 | 48.5% | 23.1% | ||
| Q2 25 | 48.8% | 27.0% | ||
| Q1 25 | 48.4% | 33.9% | ||
| Q4 24 | — | 21.4% | ||
| Q3 24 | 54.9% | 16.5% | ||
| Q2 24 | 46.1% | 34.1% | ||
| Q1 24 | 53.1% | 19.2% |
| Q4 25 | — | -30.1% | ||
| Q3 25 | -168.5% | -56.5% | ||
| Q2 25 | -118.1% | 0.2% | ||
| Q1 25 | -80.8% | 5.1% | ||
| Q4 24 | — | -19.3% | ||
| Q3 24 | -120.9% | -34.6% | ||
| Q2 24 | -134.5% | 1.5% | ||
| Q1 24 | -132.2% | -15.3% |
| Q4 25 | — | -2.2% | ||
| Q3 25 | -177.4% | -54.9% | ||
| Q2 25 | -153.7% | 1.7% | ||
| Q1 25 | -63.8% | 7.8% | ||
| Q4 24 | — | -15.7% | ||
| Q3 24 | -122.0% | -28.3% | ||
| Q2 24 | -203.3% | 5.5% | ||
| Q1 24 | -70.6% | -10.5% |
| Q4 25 | — | $-0.01 | ||
| Q3 25 | $-0.09 | $-0.04 | ||
| Q2 25 | $-0.09 | $0.01 | ||
| Q1 25 | $-0.07 | $0.00 | ||
| Q4 24 | — | $-108943126.01 | ||
| Q3 24 | $-0.07 | $-0.01 | ||
| Q2 24 | $-0.12 | $108943126.00 | ||
| Q1 24 | $-0.27 | $0.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $30.5M |
| 总债务越低越好 | — | $195.4K |
| 股东权益账面价值 | $399.7M | $141.0M |
| 总资产 | $539.6M | $153.9M |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
| Q4 25 | — | $30.5M | ||
| Q3 25 | $129.4M | — | ||
| Q2 25 | $158.6M | — | ||
| Q1 25 | $150.9M | — | ||
| Q4 24 | — | $18.2M | ||
| Q3 24 | $210.6M | $13.0M | ||
| Q2 24 | $269.8M | $12.4M | ||
| Q1 24 | $287.1M | $11.9M |
| Q4 25 | — | $195.4K | ||
| Q3 25 | — | $93.2K | ||
| Q2 25 | — | $127.5K | ||
| Q1 25 | — | $161.6K | ||
| Q4 24 | — | $327.7K | ||
| Q3 24 | $55.2M | $228.9K | ||
| Q2 24 | $55.1M | $262.1K | ||
| Q1 24 | $55.0M | $0 |
| Q4 25 | — | $141.0M | ||
| Q3 25 | $399.7M | $71.8M | ||
| Q2 25 | $424.5M | $37.5M | ||
| Q1 25 | $454.6M | $32.6M | ||
| Q4 24 | — | $28.6M | ||
| Q3 24 | $489.3M | $25.1M | ||
| Q2 24 | $510.3M | $25.7M | ||
| Q1 24 | $577.3M | $25.4M |
| Q4 25 | — | $153.9M | ||
| Q3 25 | $539.6M | $79.9M | ||
| Q2 25 | $557.0M | $47.5M | ||
| Q1 25 | $579.6M | $39.5M | ||
| Q4 24 | — | $34.6M | ||
| Q3 24 | $681.5M | $29.8M | ||
| Q2 24 | $708.7M | $28.9M | ||
| Q1 24 | $777.7M | $28.0M |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.01× | ||
| Q3 24 | 0.11× | 0.01× | ||
| Q2 24 | 0.11× | 0.01× | ||
| Q1 24 | 0.10× | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $-3.5M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $-15.2M |
| 自由现金流率自由现金流/营收 | -118.1% | -116.7% |
| 资本支出强度资本支出/营收 | 4.5% | 90.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $-37.5M |
8季度趋势，按日历期对齐
| Q4 25 | — | $-3.5M | ||
| Q3 25 | $-22.2M | $-3.9M | ||
| Q2 25 | $-20.7M | $-627.7K | ||
| Q1 25 | $-30.3M | $-1.7M | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | $-27.9M | $411.2K | ||
| Q2 24 | $-39.0M | $565.9K | ||
| Q1 24 | $-62.5M | $65.0K |
| Q4 25 | — | $-15.2M | ||
| Q3 25 | $-23.1M | $-12.5M | ||
| Q2 25 | $-22.6M | $-7.2M | ||
| Q1 25 | $-35.3M | $-2.6M | ||
| Q4 24 | — | $970.6K | ||
| Q3 24 | $-30.1M | $338.9K | ||
| Q2 24 | $-41.0M | $467.9K | ||
| Q1 24 | $-63.3M | $12.3K |
| Q4 25 | — | -116.7% | ||
| Q3 25 | -118.1% | -144.1% | ||
| Q2 25 | -103.6% | -68.0% | ||
| Q1 25 | -86.6% | -37.0% | ||
| Q4 24 | — | 17.2% | ||
| Q3 24 | -136.4% | 13.2% | ||
| Q2 24 | -182.2% | 12.8% | ||
| Q1 24 | -138.9% | 0.4% |
| Q4 25 | — | 90.1% | ||
| Q3 25 | 4.5% | 99.7% | ||
| Q2 25 | 8.7% | 62.1% | ||
| Q1 25 | 12.4% | 12.3% | ||
| Q4 24 | — | 3.7% | ||
| Q3 24 | 10.2% | 2.8% | ||
| Q2 24 | 8.6% | 2.7% | ||
| Q1 24 | 1.7% | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -3.46× | ||
| Q1 25 | — | -3.16× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.79× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
UAMY
| Antimony | $11.8M | 90% |
| Other | $1.2M | 10% |
